Tirzepatide 60 mg: Is This a Real Licensed Dose?

What the licensed evidence base was actually built on

The clinical programme behind Mounjaro did not use anything approaching 60 mg. The headline weight-loss data (an average body-weight reduction of around 20 to 21 percent over 72 weeks) came from the SURMOUNT-1 trial, published in the New England Journal of Medicine, using once-weekly subcutaneous doses of 5 mg, 10 mg, and 15 mg. The 2,539 adults in that trial never received anything close to 60 mg. The 15 mg strength is the maximum dose in the licensed schedule, reached gradually after months of titration at lower doses. Those lower steps exist because the medicine's gastrointestinal effects (nausea, loose stools, indigestion) are most noticeable early on, and a slow ramp gives the body time to settle. If you want to understand what one of those mid-range steps involves in practice, our page on tirzepatide 5 mg explains what that stage of the schedule typically looks like. The licensed dose ladder was designed around tolerability as much as efficacy, and the results it produced are the ones regulators assessed. Anything outside that framework has not been through the same safety scrutiny.

Where the "60 mg tirzepatide" figure actually comes from

Tirzepatide exists as both a licensed medicine and a raw research peptide. In research settings, tirzepatide peptide is sometimes measured and sold in microgram or milligram quantities for laboratory study, and some unregulated online suppliers list products described as "60 mg tirzepatide peptide". This is a fundamentally different context. Those products are not manufactured to the same standards as licensed medicines, are not subject to MHRA oversight, and are not intended for human self-administration. A page covering tirzepatide 60 mg peptide products goes into more detail on this distinction, but the short version is straightforward: research-grade peptides and licensed injectable medicines are not interchangeable.

The MHRA has warned publicly about unlicensed weight-loss products sold online, including counterfeit pens that have contained entirely different substances. Seeking out a higher dose or an alternative formulation from an unverified source carries real physical risk, not just a regulatory technicality.

The doses that do exist, and how prescribers choose between them

Licensed Mounjaro pens in the UK come in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, each delivering four weekly injections from a single pen. Treatment begins at 2.5 mg (a dose whose job is to let the body adjust rather than to produce significant weight loss) before stepping up roughly every four weeks as tolerated. If you want to understand the practical difference between early doses, the page on tirzepatide 2.5 mg explains what that first pen period typically involves. Some people move through the schedule faster, some stay longer at a given strength; that is always a prescriber's call, not a self-managed decision. For anyone who has reached the second step and wants a clearer sense of what comes next, our guide to 1 mg tirzepatide covers the dosing detail at that stage of titration. The Mounjaro overview covers the full picture of how the medicine works if you are earlier in your research.

A quick habit worth building before ordering anything: check the GPhC register at pharmacyregulation.org to confirm a pharmacy holds a valid premises registration. It takes under a minute and it is the fastest way to separate legitimate UK online pharmacies from unregulated sellers. Pharmacies that supply unlicensed doses or products without a prescription are not on that register, and that absence is the clearest warning sign available to you.

What this means for someone exploring weight management options

If you landed on this page because you were searching for a stronger or faster-acting form of tirzepatide, it is worth knowing that the 15 mg licensed dose already delivers substantial results in clinical evidence, and that the titration schedule exists to get you there safely. Skipping steps or sourcing products from outside the licensed supply chain does not accelerate outcomes, it removes the clinical safety net that makes those outcomes meaningful. Our page on tirzepatide 5mg is a useful reference if you want to see how one of the mid-schedule doses fits into that broader titration picture. The licensed range, properly supervised, is where the evidence sits.

For people weighing up whether injectable tirzepatide or an oral option suits them better, the weight loss treatment overview sets out what is currently available through a regulated UK pharmacy. If you are already on treatment elsewhere and thinking about transferring, a clinical team can assess your current dose and history before any prescription is issued. That kind of review (a real prescriber reading your notes, not a checkbox system) is what distinguishes a licensed service from one operating in a grey area. You can explore what that process looks like by starting a free consultation with our prescribers whenever you are ready.